This concept is followed with the approved mAb Fab fragment certolizumab pegol (α-TNF-α) used for treatment of, e.g., Crohn’s disease or RA and is thought to reduce Fc-mediated side effects. This evidence concerns the gene TNF and rheumatoid arthritis.